The University Clinical and Hospital Service of Kosovo (SHSKUK) has awarded a contract worth more than €4 million to supply 12 types of essential medicines.
According to IndeksOnline, the tender had an estimated value of €5.5 million and was divided into 14 separate lots, each covering different types of medication.
With the exception of cisplatin and piperacillin + tazobactam, the SHSKUK secured contracts for a range of other medicines.
The tender documents show the estimated prices for the contracts, and none of the medicines was awarded at a price higher than the amount initially projected.
The highest-value lot was Lot 13.
A contract worth €1,707,744.60 was awarded for 12,366 units of erythropoiesis-stimulating agents. The winning company was MEDITECH.
This medication is used to treat severe anaemia by stimulating the bone marrow to produce red blood cells.
Lot 2 covered 2,934 units of coagulation factor IX, worth €469,440. The medicine is used to treat and prevent bleeding in people with haemophilia B. Agani L.T.D. SH.P.K. was declared the winner of this lot.
For Lot 3, €704,904 was allocated for etanercept. A total of 20,432 units cost the SHSKUK nearly €705,000, with Santefarm named the winning company.
Lot 4 was allocated €187,795 for 1,633 units of trastuzumab, a medicine used to treat cancer. The contract was awarded to the group of economic operators GENE MEDICALS SH.P.K. and EDNAFARMA.
Lot 5 covered the supply of midazolam, a medicine used for sedation. MEDI MAX received €39,973.26 for 128,946 units of the medication.
The SHSKUK also secured 35,000 units of nilotinib, which is used to treat leukaemia. The supply cost €455,700, and the contract was awarded to DELTAPHARMA-KS SH.P.K.
IndeksOnline also reports the procurement of sunitinib, with €27,529.40 allocated for 4,666 units.
For the treatment of liver cancer, the SHSKUK secured 40,833 units of sorafenib. The supply cost €109,024.11, and the winning company was Santefarm.
Liri-Med won the tender to supply gemcitabine, with €335,172 allocated for 9,858 units.
For 37,800 units of imatinib, the SHSKUK awarded a contract worth €60,102 through a tender based on the lowest responsive bid. The medicine will be used to treat various types of cancer.
Meanwhile, €39,132.67 was allocated for the supply of temozolomide.
A total of 6,533 units of this medicine, supplied by MEDI MAX SH.P.K., will be available to patients requiring treatment for malignant brain tumours.
For 840 units of pemetrexed, the SHSKUK allocated €121,800.
The contract to supply this medicine, which is used to treat lung cancer, was awarded to Liri-Med.
All these medicines are included on Kosovo’s essential medicines list.
As in previous procurement rounds, the medicines will be delivered to the central pharmacy of the University Clinical Centre of Kosovo (QKUK) and the SHSKUK.
The contracts are scheduled to run for 24 months.
For the two medicines for which no contract has yet been awarded, it remains unclear whether the SHSKUK will launch a new tender.
According to IndeksOnline, the total value of the awarded contracts is €4,258,317.04.
The contract documents can be accessed here.
